Buğday İrfan, İnanç Mevlüde, Özkan Metin, Bozkurt Oktay, Coşar Ramazan, Firat Sedat Tarik, Mutlu Emel, Eser Murat, Dişli Ahmet Kürşad, Cengiz Muhammet
Medical Oncology Department, Erciyes University Medical School, Kayseri, Türkiye.
Anticancer Drugs. 2025 Feb 1;36(2):135-139. doi: 10.1097/CAD.0000000000001670. Epub 2024 Nov 27.
Small cell lung cancer (SCLC) constitutes around 15% of lung cancer cases and stands as the primary cause of cancer-related fatalities in men and the second leading cause in women globally. In this study, our objective was to evaluate the levels of C-reactive protein (CRP) and procalcitonin (PCT) in newly diagnosed extensive-stage SCLC patients without evidence of infection. We aimed to demonstrate that elevated CRP and PCT levels may not solely indicate infection but could also be elevated in malignancies. Furthermore, we sought to correlate these marker levels with patient and disease characteristics to elucidate the relationship between these inflammation markers and disease progression. A total of 115 patients who were pathologically and radiologically diagnosed with extensive-stage SCLC between January 2020 and December 2022 and who had received no prior treatment were included in the study. The Kaplan-Meier analysis revealed a median progression-free survival (PFS) of 7.46 months [95% confidence interval (CI), 6.85-8.07] and a median overall survival (OS) of 10.50 months (95% CI, 8.69-12.30) for all patients. In the group with elevated PCT, the median PFS was 6.73 months (95% CI, 3.92-9.54), whereas it was 7.86 months (95% CI, 7.13-8.59) in the group with normal PCT ( P = 0.002). Similarly, the median OS was 9.10 months (95% CI, 5.61-12.58) in the elevated PCT group and 11.66 months (95% CI, 9.59-13.74) in the normal PCT group ( P = 0.006). Patients with elevated procalcitonin (PRC) levels at the time of diagnosis exhibited shorter PFS and OS durations compared to patients with normal PRC levels. Furthermore, elevated CRP has also been demonstrated to correlate with poorer prognosis in extensive-stage SCLC.
小细胞肺癌（SCLC）约占肺癌病例的15%，是全球男性癌症相关死亡的主要原因，在女性中是第二大主要原因。在本研究中，我们的目的是评估新诊断的广泛期小细胞肺癌患者在无感染证据时的C反应蛋白（CRP）和降钙素原（PCT）水平。我们旨在证明，CRP和PCT水平升高可能不仅表明存在感染，在恶性肿瘤中也可能升高。此外，我们试图将这些标志物水平与患者及疾病特征相关联，以阐明这些炎症标志物与疾病进展之间的关系。本研究纳入了2020年1月至2022年12月期间经病理和放射学诊断为广泛期小细胞肺癌且未接受过先前治疗的115例患者。Kaplan-Meier分析显示，所有患者的无进展生存期（PFS）中位数为7.46个月[95%置信区间（CI），6.85 - 8.07]，总生存期（OS）中位数为10.50个月（95%CI，8.69 - 12.30）。在PCT升高组中，PFS中位数为6.73个月（95%CI，3.92 - 9.54），而在PCT正常组中为7.86个月（95%CI，7.13 - 8.59）（P = 0.002）。同样，PCT升高组的OS中位数为9.10个月（95%CI，5.61 - 12.58），正常PCT组为11.66个月（95%CI，9.59 - 13.74）（P = 0.006）。与PCT水平正常的患者相比，诊断时PCT水平升高的患者的PFS和OS持续时间更短。此外，CRP升高也已被证明与广泛期小细胞肺癌的预后较差相关。
